CD47

CD47 antibody LS-C811769 is an FITC-conjugated mouse monoclonal antibody to CD47 from human. It is reactive with human, mouse and rat. Validated for Flow.

Antibodies Primary

Article No

LS-C811769-200

Application

FC

Size

200 tst

Clone

MIAP410

Source / Host

mouse

Shipping Information

RT

Species Reactivity

human
mouse
rat

Article No

LS-C811769-200

Application

FC

Size

200 tst

Clone

MIAP410

Source / Host

mouse

Shipping Information

RT

Species Reactivity

human
mouse
rat

Specifications

NCBI Number 961
Application FC
Article No LS-C811769-200
Country Availability SE, FI, DK, NO, FO, GL
Clone MIAP410
Clone Type monoclonal
Conjugation FITC
Description CD47 antibody LS-C811769 is an FITC-conjugated mouse monoclonal antibody to CD47 from human. It is reactive with human, mouse and rat. Validated for Flow.
Supplier LifeSpan Biosciences
Entrez Gene ID 961
Gene Symbol CD47
Isotype IgG1 k
Notes CD47 antibody LS-C811769 is an FITC-conjugated mouse monoclonal antibody to CD47 from human. It is reactive with human, mouse and rat. Validated for Flow.
Alias Names CD47, CD47 antigen, CD47 molecule, Integrin associated protein, Integrin-associated protein, Leukocyte surface antigen CD47, MER6, Protein MER6, Rh-related antigen, OA3, CD47 glycoprotein, IAP
Product Type Antibodies Primary
Protocol Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The amount of the reagent is suggested to be used 5 µL of antibody per test (million cells in 100 µl staining volume or per 100 µl of whole blood). Please check your vial before the experiment. Since applications vary, the appropriate dilutions must be determined for individual use.
Shipping Information RT
Size 200 tst
Source / Host mouse
Species Reactivity human, mouse, rat
Storage 4°C
Substrate / Buffer PBS, 0.05% ProClin™ 300, 1% BSA
Product Page Updated 2024-04-12T11:52:25.099Z
Volume 200 tst

Suggested protocols

Shipping info
The delivery time for this item is approximately 9-18 business days. Read more